---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-073555"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T03:00:04.794147+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Syndax names Dr. Nicholas Botwood Head of R&D and CMO, replacing Neil Gallagher

## Summary
- Dr. Nicholas Botwood appointed Head of R&D and CMO, effective May 12, 2025; succeeds Dr. Neil Gallagher who is departing.
- Botwood most recently SVP, Head of Worldwide Medical Oncology at BMS; brings 25+ years oncology development experience.
- Employment terms: base salary $540K, annual target bonus 45%, stock option for 215K shares, PRSU of 23,400 units.
- Gallagher will remain for interim transition period; thanked for contributions including two product approvals.
- Annual meeting results: all director nominees elected, say-on-pay approved (62.5M for), auditor ratified.

## SEC filing metadata
- accession: 0000950170-25-073555
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017025073555/0000950170-25-073555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017025073555/sndx-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-073555
- JSON: https://secwatch.observer/filing/0000950170-25-073555.json
- Plain text: https://secwatch.observer/filing/0000950170-25-073555.txt

## Key facts
- Executive change
  Nicholas A.J. Botwood was appointed as Head of Research and Development, Chief Medical Officer at Syndax Pharmaceuticals Inc.
  - Action: appointed
  - Role: Head of Research and Development, Chief Medical Officer
  source text: Nicholas A.J. Botwood, BSC (HONS), MB BS, MFPM, FRCP, will join the Company as Head of Research and Development, Chief Medical Officer, effective May 12, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017025073555/0000950170-25-073555-index.htm
- Executive change
  Neil Gallagher resigned as President, Head of Research and Development at Syndax Pharmaceuticals Inc.
  - Action: resigned
  - Role: President, Head of Research and Development
  source text: Neil Gallagher, M.D. Ph.D, President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017025073555/0000950170-25-073555-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.